Related Experiment Videos
[Mesenteric infarction secondary to antithrombin III deficiency]
M Miguil1, C el Kettani, S Salmi
1Service d'Anesthésie-Réanimation des urgences chirurgicales, CHU Ibn Rochd, Casablanca, Maroc.
Cahiers D'Anesthesiologie
|January 1, 1996
Summary
Antithrombin III deficiency, a cause of blood clots, was transiently observed in a woman using oral contraceptives. This case highlights the need to manage risk factors for venous thrombosis in acquired AT III deficiency.
Area of Science:
- Hematology
- Vascular Medicine
- Pharmacology
Background:
- Antithrombin III (AT III) is a critical physiological inhibitor of thrombin, playing a vital role in regulating blood coagulation.
- Deficiency in AT III activity predisposes individuals to an increased risk of thromboembolic events, particularly venous thrombosis.
Observation:
- A case report details a 42-year-old woman who experienced mesenteric venous infarction.
- The patient's AT III deficiency was identified as transient and directly linked to the use of oral contraceptives.
Findings:
- Acquired Antithrombin III deficiency can precipitate serious thrombotic events such as mesenteric venous infarction.
- Oral contraceptives were identified as the causative agent for the transient AT III deficiency in this patient.
Implications:
- This case underscores the importance of considering medication-induced AT III deficiency in patients presenting with unexplained venous thrombosis.
- Management strategies for patients with acquired AT III deficiency must focus on identifying and mitigating all associated risk factors for venous thromboembolism.